

-5-

**REMARKS**

**STATUS OF CLAIMS**

Claim 15 has been canceled. Claim 18 has been amended for greater clarity. Claims 10, 13, 14, and 16-26 are pending. Support for this claim amendment can be found throughout the specification and in the originally filed claims.

**REJECTIONS UNDER 35 U.S.C. § 112, first paragraph**

**Claims 10, 13, 14, and 16-26 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement.**

Applicants contend that one of skill in the art could readily practice the present invention.

Claim 10 (from which Claims 13, 14, and 16-26 depend) is directed to a method for treating an individual suffering from a wound comprising administering an effective amount of a lymphotactin (XCL1) to the individual, whereby administration of the lymphotactin (XCL1) accelerates wound healing.

Regarding the allegation that the specification “does not hypothesize what role XCL1 plays in wound healing (*e.g.*, enhances reepithelialization, growth factor for fibroblasts, *etc.*),” Applicants point out that, “an inventor need not know how or why his or her invention does work in order to obtain a patent.” Enzo Biochem, Inc. v. Calgene, Inc., 188 F.3d 1362, 1375 (Fed. Cir. 1999), citing Newman v. Quigg, 877 F.2d 1575 (Fed. Cir. 1989). Consequently, Applicants do not need to understand how XCL1 accelerates wound healing to obtain a patent, but rather only that this is the end result.

Applicants disagree that Hedrick *et al.* (U.S. Patent 6,022,534) teach against administering XCL1 to enhance cell growth, such as is desirable at a wound. Rather, Hedrick *et al.* do not address whether XCL1 activity is desirable to promote wound healing.

-6-

Hedrick *et al.* teach that XCL1 increases the number of various lymphocytes either by attracting cytotoxic T lymphocytes (CTL) and/or natural killer cells (NK), and/or inducing proliferation of resident cells. (Hedrick *et al.*, col 2, lines 17-22). In particular, increasing the number of such lymphocytes at a location where there are tumor cells in an animal is preferred. (Hedrick *et al.*, col 2, lines 44-54).

Hedrick *et al.* also teach that “an antagonist will be effective in preventing the recruitment of such cells. This may be important, *e.g.*, in a transplantation context, where NK and/or CTL function is harmful.” (Hedrick *et al.*, col 2, lines 30-34).

Hedrick *et al.*, thereby suggest the local environment dictates whether XCL1 activity is or is not desirable.

The following articles (abstracts of which are enclosed herein) support the nexus between XCL1 activity and wound healing.

- Boismenu *et al.*, “Chemokine expression by intraepithelial gamma delta T cells. Implications for the recruitment of inflammatory cells to damaged epithelia” *J Immunol*, **157**(3):985-992 (1996).  
XCL1 was shown to be inducible in dendritic epidermal T cells (DETC) 7-17 and the most abundant chemokine produced by activated DETC 7-17 cells (amongst those examined MIP-1alpha, MIP-1 beta, and RANTES). Similarly, copious amounts of XCL1 mRNA was produced by activated primary DETC cultures as well as activated freshly isolated intestinal intraepithelial T cells (I-IEL) (with T cells expressing gamma delta). Migration of CD8+ T cells induced by culture supernatants from stimulated DETC 7-17 cells (which contain XCL1) was strongly reduced in the presence of neutralizing anti-XCL1 antiserum. Authors suggest gamma delta IEL play a role in the maintenance of epithelia homeostasis.
- Huang *et al.*, “Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin,” *Biochem Biophys Res Commun*, **281**(2):378-382 (Feb 2001).  
XCL1 shown to be chemotactic for B lymphocytes and neutrophils as well as T lymphocytes. In addition, expression of XCR1 (the receptor for XCL1) found only in association with these cells. Authors suggest that XCL1 plays a key role in the regulation of T and B lymphocytes, and neutrophil trafficking, and thereby their roles in inflammatory and immunological responses.

-7-


In view of the guidance available at the time of filing, for example, as noted above, Applicants submit that undue experimentation would not be required to practice the present invention as defined by the amended claims. Additional support for how to administer XCL1 to accelerate wound healing can be found throughout specification, for example, on page 11, line 14 to page 12, line 2 as well as on page 14, line 1 to page 17, lines 26.

In light of the above arguments, Claims 10, 13, 14, and 16-26 are believed to be enabled by the specification. As such, Applicants respectfully request withdrawal of this rejection under 35 U.S.C. § 112, first paragraph.

**CONCLUSION**

It is believed that the foregoing amendment places this application now in condition for allowance. Therefore, favorable action allowing pending Claims 10, 13, 14, and 16-26 is respectfully solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'S. Zaradic', is written over a horizontal line.

SCHERING-PLOUGH CORPORATION  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, New Jersey 07033-0530  
Fax: 908-298-5388

Sandy Zaradic, Ph.D.  
Reg. No. 45,997  
Patent Agent for Applicants  
(908) 298-7221



**PubMed**

National  
Library  
of Medicine

Entrez PubMed

for Nucleotide Protein Genome Structure PMC Journals Books  
Limits Preview/Index History Clipboard Details

About Entrez

Text Version

☐ 1: J Immunol. 1996 Aug 1; 157(3): 985-92.

Related Articles, Links

Entrez PubMed  
Overview  
Help | FAQ  
Tutorial  
New/Noteworthy  
E-Utilities

PubMed Services  
Journals Database  
MASH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central  
Privacy Policy

Display Abstract Show: 20 Sort Send to Text

## Chemokine expression by intraepithelial gamma delta T cells. Implications for the recruitment of inflammatory cells to damaged epithelia.

Boismenu R, Feng L, Xia YY, Chang JC, Havran WL.

Department of Immunology, The Scripps Research Institute, La Jolla, CA 92037, USA.

T cells expressing gamma delta TCR may have evolved to recognize Ag in a different manner as well as perform a broader set of functions than T cells with alpha beta TCR. In this study, we tested the hypothesis that dendritic epidermal T cells (DETC) bearing the invariant V gamma 3V delta 1 TCR may be able to signal the migration of peripheral alpha beta T cells to the epidermis by secreting specific chemokines. Expression of macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta, RANTES, and lymphotactin was inducible in DETC 7-17 cells, whereas mRNA for monocyte chemoattractant protein (MCP)-1 could not be detected. Strikingly, lymphotactin was the most abundant chemokine produced by activated DETC 7-17 cells. Activated primary DETC cultures also produced copious amounts of lymphotactin mRNA. Similarly, freshly isolated and activated intestinal intraepithelial T cells (I-IEL) with gamma delta TCR expressed high levels of lymphotactin mRNA. In contrast, lymphotactin mRNA was present in activated spleen gamma delta T cells at low basal levels. Migration of CD8+ T cells induced by culture supernatants from stimulated DETC 7-17 cells was strongly reduced in the presence of a neutralizing anti-lymphotactin antiserum and to a lesser extent by neutralizing anti-MIP-1 alpha, anti-MIP-1 beta, or anti-RANTES antiserum. The presence of lymphotactin in supernatants from activated DETC 7-17 cultures was directly demonstrated by Western blot analysis. These observations are consistent with a model in which gamma delta IEL play an active multi-faceted role in the maintenance of epithelia homeostasis.

PMID: 8757601 [PubMed - indexed for MEDLINE]

Display Abstract Show: 20 Sort Send to Text



**PubMed**

National  
Library  
of Medicine  
NLM

Entrez PubMed

Nucleotide

Protein

Genome

Structure

PMC

Journals

Books

Search PubMed

for

Limits

Preview/Index

History

Clipboard

Details

Go Clear

About Entrez

Text Version

Display Abstract

Show: 20

Sort

Send to Text

☐ 1: Biochem Biophys Res Commun. 2001 Feb 23; 281(2): 378-82.

ELSEVIER  
FULL-TEXT ARTICLE

**Neutrophils and B cells express XCRI receptor and chemotactically respond to lymphotactin.**

Huang H, Li F, Cairns CM, Gordon JR, Xiang J.

Department of Microbiology, College of Medicine, Saskatoon Cancer Center, University of Saskatchewan, Saskatoon, Saskatchewan S7N 0W0, Canada.

The C chemokine lymphotactin (Lpn) has been reported to act specifically on CD4(+) and CD8(+) T lymphocytes and natural killer (NK) cells, but not monocytes. However, the chemotactic effect of Lpn on other types of hematopoietic cells has not been well studied. In this study we investigated (i) the chemotactic influences of Lpn on T and B lymphocytes, neutrophils, monocytes, and dendritic cells, and (ii) the expression of the Lpn receptor (XCRI) by these cells, using RT-PCR. Our data showed that Lpn is chemotactic for B lymphocytes and neutrophils as well as T lymphocytes, but not for monocytes or dendritic cells, and that XCRI expression is found only in association with T and B lymphocytes and neutrophils, but not monocytes or dendritic cells. Thus, this study is the first demonstration of a chemotactic effect of Lpn on neutrophils and confirms the association of this effect with expression of the XCRI receptor on these cells. These data suggest that Lpn could potentially be an important protein in the regulation of T and B lymphocytes and neutrophil trafficking, and thereby also their roles in inflammatory and immunological responses. Copyright 2001 Academic Press.

PMID: 11181058 [PubMed - indexed for MEDLINE]

Privacy Policy

PubMed Services  
Journals Database  
MeSH Database  
Single Citation Matcher  
Batch Citation Matcher  
Clinical Queries  
LinkOut  
Cubby

Related Resources  
Order Documents  
NLM Gateway  
TOXNET  
Consumer Health  
Clinical Alerts  
ClinicalTrials.gov  
PubMed Central

Display Abstract

Show: 20

Sort

Send to Text

Write to the Help Desk

NCBI | NLM | NIH

Department of Health & Human Services  
Freedom of Information Act | Disclaimer

Jan 14 2004 16:08:52